EU Approves Zurzuvae, a Breakthrough for Postpartum Depression
The European Commission has granted marketing authorization for Biogen’s Zurzuvae (zuranolone) to treat postpartum depression in adults, establishing the...
Rezolute Reports Q4 and Full-Year 2025 Financial Results
Rezolute reported fiscal Q4 and full-year 2025 results alongside two pivotal updates for its lead asset, Ersodetug: completion of...
PCI Biotech Half-Year 2025 Report: A Complete Analysis
PCI Biotech has halted development of its photochemical lysis platform intended to boost adeno-associated virus manufacturing yields. It is...
Rakovina Therapeutics Details Q2 2025 Financial Results
Rakovina Therapeutics reported a Q2 2025 net loss of C$2.92 million on operating expense cash burn of approximately C$2.65...
Windtree Stockholders Approve Key Profit Growth Proposals
Windtree Therapeutics has secured stockholder approval to pivot its business away from in‑house drug development and toward environmental services,...
Revealing Rezolute’s Full Year & Q4 2025 Financial Results
Rezolute completed enrollment in sunRIZE, its registrational Phase 3 study of ersodetug in congenital hyperinsulinism (HI), with topline data...
Roche Enters Merger Agreement to Acquire 89bio for MASH Drug
Roche has signed a definitive agreement to acquire 89bio for $14.50 per share in cash plus a non-tradeable CVR...
Bright Green Eyes $10B Federal Plant-Based Drug Contract
Pharmagri Capital Partners has outlined an aggressive plan to build a sovereign, vertically integrated “seed-to-prescription” platform targeting roughly $10...
Marine Biologics & MQS Partner to Accelerate Development
Marine Biologics has struck an exclusive strategic partnership with Molecular Quantum Solutions to commercialize MQS’s physics-based modeling and machine...
Spyglass Pharma Appoints Anand Sundaram as Commercial Head
Spyglass Pharma has named Anand Sundaram as vice president, head of commercial, as the company advances its intraocular lens–mounted,...